Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelemicsXKRX:331920 -0.07%46 Market Cap is ₩160,455 Mil as of Sep. 03, 2026. GuruFocus rates XKRX:331920 with a GF Score™ of 46/100 and a GF Value™ of ₩2,756.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 860 Medical Devices & Instruments companies, Celemics ranks worse than 50.35% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Celemics's share price for the quarter that ended in Jun. 2026 was ₩11970. Celemics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 11 Mil. Therefore, Celemics's market cap for the quarter that ended in Jun. 2026 was ₩133,849 Mil.
Celemics's quarterly market cap
increased
from Dec. 2025 (₩22,165 Mil) to Mar. 2026 (₩103,030 Mil) and
increased
from Mar. 2026 (₩103,030 Mil) to Jun. 2026 (₩133,849 Mil).
Celemics's annual market cap
declined
from Dec. 2023 (₩34,534 Mil) to Dec. 2024 (₩26,737 Mil) and
declined
from Dec. 2024 (₩26,737 Mil) to Dec. 2025 (₩22,165 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Celemics's Enterprise Value for Today is ₩138,555 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Celemics Market Cap Related Terms
Celemics Market Cap Historical Data
* Premium members only.
The historical data trend for Celemics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:331920 vs ABT, SYK, MDT: Market Cap Comparison
For the Medical Devices subindustry, Celemics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celemics Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Celemics's Market Cap distribution charts can be found below:
* The bar in red indicates where Celemics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Celemics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celemics (XKRX:331920) has a Market Cap of ₩160,455 Mil as of Sep. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Celemics and its competitors. According to the industry distribution chart, Celemics ranks #433 out of 860 companies in the Medical Devices & Instruments industry, placing it in the top 50.3%.
Is Celemics' Market Cap too high?
Celemics' current Market Cap is ₩160,455 Mil. Based on the distribution chart, Celemics ranks #433 out of 860 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Celemics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celemics' Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Celemics ranks #433 out of 860 companies for Market Cap. This places Celemics in the lower half of its industry. The industry median Market Cap is 120.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 120.96, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Celemics and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 120.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celemics's current Market Cap is ₩160,455 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celemics stock overvalued right now?
Based on GuruFocus' analysis, Celemics (XKRX:331920) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩2,756.25, compared to a current price of ₩14,350.00 — trading 420.6% above its estimated fair value. The current Market Cap is ₩160,455 Mil. Celemics' overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Celemics (XKRX:331920), the current Market Cap is ₩160,455 Mil as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celemics (XKRX:331920) Overvalued in 2026?
Based on GuruFocus' analysis, Celemics stock appears to be overvalued.
The current stock price of ₩14,350.00 is trading 420.6% above its estimated GF Value™ of ₩2,756.25.
GuruFocus considers Celemics to be Significantly Overvalued.
Key valuation signals for XKRX:331920:
Market Cap: ₩160,455 Mil
GF Value™: ₩2,756.25 vs. price of ₩14,350.00 (420.6% above fair value)
No single metric tells the full story. See the XKRX:331920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celemics Inc is a manufacturer of Next Generation Sequencing test kit. It offers, develops and manufactures proprietary DNA and genetic sequencing test kits and panels. Its products include Targeted Sequencing Kit, NGS Library Preparation Kit, and XSEP MagBead.
46GF Score
Get the complete analysis for XKRX:331920
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:331920 has been successfully added to your 
